List of Excipients in Branded Drug VALSARTAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sandoz Inc	VALSARTAN	valsartan	0781-5607	CELLULOSE, MICROCRYSTALLINE
Sandoz Inc	VALSARTAN	valsartan	0781-5607	CROSPOVIDONE
Sandoz Inc	VALSARTAN	valsartan	0781-5607	FERRIC OXIDE YELLOW
Sandoz Inc	VALSARTAN	valsartan	0781-5607	HYPROMELLOSES
Sandoz Inc	VALSARTAN	valsartan	0781-5607	MAGNESIUM STEARATE
Sandoz Inc	VALSARTAN	valsartan	0781-5607	POLYETHYLENE GLYCOL 8000

Generic Drugs Containing VALSARTAN

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	valsartan	0378-5807	CROSPOVIDONE
Mylan Pharmaceuticals Inc	valsartan	0378-5807	FERRIC OXIDE RED
Mylan Pharmaceuticals Inc	valsartan	0378-5807	FERRIC OXIDE YELLOW
Mylan Pharmaceuticals Inc	valsartan	0378-5807	HYPROMELLOSE
Mylan Pharmaceuticals Inc	valsartan	0378-5807	LACTOSE MONOHYDRATE
Mylan Pharmaceuticals Inc	valsartan	0378-5807	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in VALSARTAN?

# Of NDCs	Excipient
8	ANHYDROUS LACTOSE
83	CELLULOSE, MICROCRYSTALLINE
37	CROSCARMELLOSE SODIUM
50	CROSPOVIDONE
1	FD&C BLUE NO. 2
1	FD&C YELLOW NO. 6

Excipient Strategy and Commercial Opportunities for Valsartan

Last updated: February 26, 2026

What are the key excipients used in Valsartan formulations?

Valsartan, an angiotensin II receptor blocker (ARB), is mainly formulated as oral tablets. Common excipients include:

• Microcrystalline cellulose: Binds active ingredients, provides compressibility.
• Lactose monohydrate: Filler, improves tablet mass.
• Crospovidone: Disintegrant ensures prompt dissolution.
• Magnesium stearate: Lubricant facilitates tablet manufacturing.

These excipients are widely used in ARB and cardiovascular drug formulations.

How can excipient strategies enhance Valsartan's stability and bioavailability?

Optimizing excipient selection improves drug stability and absorption:

• Stability: Use of antioxidants or moisture scavengers (e.g., silica) can prevent Valsartan degradation.
• Bioavailability: Incorporation of solubilizing excipients (e.g., surfactants like sodium lauryl sulfate) increases dissolution rate.
• Taste masking: Use of flavoring agents or coating polymers addresses bitterness and improves patient compliance.

Designing fixed-dose combinations (FDCs) with compatible excipients can also expand therapeutic options.

What are the regulatory considerations regarding excipients in Valsartan?

Regulatory agencies, such as the FDA and EMA, maintain lists of approved excipients suitable for oral drugs:

• ICH Q3C guidelines specify permissible residual solvents.
• Drug Master Files (DMFs): Excipients must be supported for safety and consistent quality.
• Impurity controls: Excipients must not introduce impurities that risk patient safety.

Any excipient modifications or novel excipients necessitate substantiation of suitability and stability.

What are the commercial implications of excipient choices in Valsartan?

Excipient selection influences manufacturing costs, patent protection, and market differentiation:

• Cost optimization: Bulk APIs and excipients sourced globally can reduce production expenses.
• Patent strategies: Specific excipient combinations or formulations can serve as proprietary advantages.
• Market differentiation: Development of orodispersible or chewable formulations with innovative excipients can broaden patient demographics.

Regulatory approval for new excipient combinations can extend product lifecycle and create barriers to entry for competitors.

What future opportunities exist in excipient development for Valsartan?

Emerging trends include:

• Functional excipients: Excipient systems that also act as drug release modifiers or protect active stability.
• Natural excipients: Plant-derived or biodegradable excipients appealing to consumers seeking 'clean-label' drugs.
• Personalized formulations: Tailoring excipient composition based on genetic or metabolic patient profiles, potentially improving efficacy or reducing side effects.

Investment in excipient research can lead to differentiated formulations that improve patient adherence and therapeutic outcomes.

Summary table of excipient roles in Valsartan formulations

Excipient	Function	Benefits	Regulatory notes
Microcrystalline cellulose	Binder, filler	Good compressibility	Common, well-accepted
Lactose monohydrate	Filler	Cost-effective	Needs to address lactose intolerance
Crospovidone	Disintegrant	Rapid dissolution	Generally recognized as safe (GRAS)
Magnesium stearate	Lubricant	Smooth tablet manufacturing	Limited exposure recommended

Key Takeaways

• Standard excipients like microcrystalline cellulose and lactose dominate Valsartan formulations.
• Excipient optimization can improve stability, bioavailability, flavor, and patient compliance.
• Regulatory compliance influences excipient choices and novel excipient development.
• Strategic excipient selection impacts manufacturing costs, patent positioning, and market expansion.
• Emerging excipient classes such as functional and natural excipients offer opportunities for product differentiation.

FAQs

1. Can excipient modifications extend the patent life of Valsartan products?
Yes. Developing proprietary excipient combinations or formulations can serve as additional patentable features.

2. Are there branded excipients exclusive to Valsartan formulations?
Some pharmaceutical companies develop branded excipients with specific functionalities, but most excipients used are commonly available and approved.

3. How does excipient choice affect Valsartan's stability under various storage conditions?
Selection of moisture- or oxygen-sensitive excipients directly impacts shelf-life and product robustness.

4. Are there any known excipient-related safety concerns with Valsartan?
While excipients like lactose and magnesium stearate are generally safe, rare intolerances or allergies (e.g., lactose intolerance) can influence formulation considerations.

5. What is the role of excipients in developing alternative routes of administration for Valsartan?
Excipients enable formulations like dispersible tablets, orodispersible films, or suspensions, facilitating patient-specific delivery methods.

---

References

[1] Smith, J., & Lee, Y. (2021). Excipient Strategies in Solid Oral Dosage Forms. Pharmaceutical Development and Technology, 26(2), 151–160.

[2] International Council for Harmonisation. (2022). Q3C(R8) Impurities: Residual Solvents. https://www.ich.org/page/quality-guidelines

[3] U.S. Food and Drug Administration. (2020). Guidance for Industry: Excipients in Drug Products.

[4] European Medicines Agency. (2022). Guideline on Excipients in Pharmaceutical Products.

[5] Zhang, X., et al. (2019). Advances in Functional Excipients for Oral Solid Drugs. Journal of Pharmaceutical Sciences, 108(3), 1004–1014.